March 1, 2021

Safe International IBU CUP in Osrblie-Brezno thanks to tests from MultiplexDX

International events are due to COVID-19 a major challenge for organizers. Despite the unfavorable epidemiological situation in Slovakia, the Slovak Biathlon Association managed to organize the 3. and 4. rounds of the European Biathlon Cup IBU CUP BREZNO - OSRBLIE without one case of COVID-19 infection among the participants.

MultiplexDX, as a partner of the sporting event, donated its rTEST COVID-19 qPCR Multiplex kits. According to the Slovak Biathlon Association, this was the first biathlon event worldwide this year that managed to go without any COVID-19 infection among the participants. Sportsmen and their teams were already tested by MultiplexDX RT-PCR tests during accreditation, but also during the two-week event. Five positive participants were captured during pre-accreditation testing.

Congratulations to the organizers on a well-managed event, a well-managed "bubble", and to the athletes for their results.

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter


MultiplexDX News